RxDoctor Payments Data

Fadi Daher, MD

Nephrology · Memphis, TNNPI 1164554572

Payments from drug & device makers

$6,076in general payments, 2019–2025

Across 268 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$969
  • Mallinckrodt Hospital Products Inc.$935
  • Fresenius USA Marketing, Inc.$884
  • Bayer$485
  • Amgen$426
  • Otsuka America Pharmaceutical, Inc.$391
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$5,61392%
  • Education$4638%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,076 in reported general payments places this provider in the 70th percentile of 229 nephrology providers in Tennessee.

See all nephrology providers in Tennessee

Medicare billing

Part B allowed, 2024
$269,638
Medicare patients
596
Services billed
2,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide253$596,309
FarxigaDapagliflozin Propanediol48$52,111
LokelmaSodium Zirconium Cyclosilicate56$46,953
VeltassaPatiromer Calcium Sorbitex24$45,210
JanuviaSitagliptin Phosphate50$42,458
AuryxiaFerric Citrate23$38,268
EliquisApixaban17$27,376
Sevelamer Carbonate152$25,983
Midodrine Hcl15$2,283
Hydralazine Hcl102$2,016
Calcitriol99$1,482
Amlodipine Besylate203$1,013
Metolazone30$891
Furosemide164$887
Carvedilol86$572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$884$596,309253 claims
AstraZenecaFarxiga, Lokelma$969$99,064104 claims
Akebia Therapeutics IncAuryxia$60$38,26823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 229 nephrology providers in Tennessee.

Other nephrology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →